-
Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal
Giovanni Barosi
Drug Evaluation: Clinical Investigation
-
Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal
Giovanni Barosi
Drug Evaluation: Clinical Investigation
-
Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal
Giovanni Barosi
Drug Evaluation: Clinical Investigation
-
Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal
Giovanni Barosi
Drug Evaluation: Clinical Investigation
-
Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal
Giovanni Barosi
Drug Evaluation: Clinical Investigation
-
Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal
Giovanni Barosi
Drug Evaluation: Clinical Investigation
-
Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal
Giovanni Barosi
Drug Evaluation: Clinical Investigation
-
Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal
Giovanni Barosi
Drug Evaluation: Clinical Investigation
-
Surrogate end points: when should they be used?
Geert Molenberghs, Ariel Alonso Abad, Wim van der Elst, Tomasz Burzykowski, Marc Buyse
Review Article: Clinical Investigation
-
Surrogate end points: when should they be used?
Geert Molenberghs, Ariel Alonso Abad, Wim van der Elst, Tomasz Burzykowski, Marc Buyse
Review Article: Clinical Investigation
-
Surrogate end points: when should they be used?
Geert Molenberghs, Ariel Alonso Abad, Wim van der Elst, Tomasz Burzykowski, Marc Buyse
Review Article: Clinical Investigation
-
Surrogate end points: when should they be used?
Geert Molenberghs, Ariel Alonso Abad, Wim van der Elst, Tomasz Burzykowski, Marc Buyse
Review Article: Clinical Investigation
-
Surrogate end points: when should they be used?
Geert Molenberghs, Ariel Alonso Abad, Wim van der Elst, Tomasz Burzykowski, Marc Buyse
Review Article: Clinical Investigation
-
Surrogate end points: when should they be used?
Geert Molenberghs, Ariel Alonso Abad, Wim van der Elst, Tomasz Burzykowski, Marc Buyse
Review Article: Clinical Investigation
-
Surrogate end points: when should they be used?
Geert Molenberghs, Ariel Alonso Abad, Wim van der Elst, Tomasz Burzykowski, Marc Buyse
Review Article: Clinical Investigation
-
Surrogate end points: when should they be used?
Geert Molenberghs, Ariel Alonso Abad, Wim van der Elst, Tomasz Burzykowski, Marc Buyse
Review Article: Clinical Investigation
-
Anti-MET Targeted therapy for NSCLC: has it come of age?
Patrick C Ma
Editorial: Clinical Investigation
-
Anti-MET Targeted therapy for NSCLC: has it come of age?
Patrick C Ma
Editorial: Clinical Investigation
-
Anti-MET Targeted therapy for NSCLC: has it come of age?
Patrick C Ma
Editorial: Clinical Investigation
-
Anti-MET Targeted therapy for NSCLC: has it come of age?
Patrick C Ma
Editorial: Clinical Investigation
-
Anti-MET Targeted therapy for NSCLC: has it come of age?
Patrick C Ma
Editorial: Clinical Investigation
-
Anti-MET Targeted therapy for NSCLC: has it come of age?
Patrick C Ma
Editorial: Clinical Investigation
-
Anti-MET Targeted therapy for NSCLC: has it come of age?
Patrick C Ma
Editorial: Clinical Investigation
-
Anti-MET Targeted therapy for NSCLC: has it come of age?
Patrick C Ma
Editorial: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 1, No 2
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 1, No 2
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 1, No 2
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 1, No 2
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 1, No 2
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 1, No 2
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 1, No 2
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 1, No 2
Acknowledgements: Clinical Investigation
-
Targeting the BLyS family in autoimmunity: a tale of mouse and man
Jean L Scholz, Eline T Luning Prak, Michael P Cancro
Therapeutic Prospective: Clinical Investigation
-
Targeting the BLyS family in autoimmunity: a tale of mouse and man
Jean L Scholz, Eline T Luning Prak, Michael P Cancro
Therapeutic Prospective: Clinical Investigation
-
Targeting the BLyS family in autoimmunity: a tale of mouse and man
Jean L Scholz, Eline T Luning Prak, Michael P Cancro
Therapeutic Prospective: Clinical Investigation
-
Targeting the BLyS family in autoimmunity: a tale of mouse and man
Jean L Scholz, Eline T Luning Prak, Michael P Cancro
Therapeutic Prospective: Clinical Investigation
-
Targeting the BLyS family in autoimmunity: a tale of mouse and man
Jean L Scholz, Eline T Luning Prak, Michael P Cancro
Therapeutic Prospective: Clinical Investigation
-
Targeting the BLyS family in autoimmunity: a tale of mouse and man
Jean L Scholz, Eline T Luning Prak, Michael P Cancro
Therapeutic Prospective: Clinical Investigation
-
Targeting the BLyS family in autoimmunity: a tale of mouse and man
Jean L Scholz, Eline T Luning Prak, Michael P Cancro
Therapeutic Prospective: Clinical Investigation
-
Targeting the BLyS family in autoimmunity: a tale of mouse and man
Jean L Scholz, Eline T Luning Prak, Michael P Cancro
Therapeutic Prospective: Clinical Investigation